Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS EXON 2 MUTATION
KRAS EXON 2 MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- 31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations. Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1326
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/75
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Irinotecan,Selumetinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25322874
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Irinotecan | Sensitivity | true |
| Selumetinib | Sensitivity | true |